UNSPSC 51384609: Oxyphenbutazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H806S4B3NS, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl- (van) (8ci) but generally known as oxyphenbutazone, which bears US NIH Compound Identifier 4641. European Medicines Agency schedules Oxyphenbutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09572MIG.

UNSPSC 51384609 Oxyphenbutazone is a Commodity-level code that does not align with the state and local procurement activity actually being solicited under it. The recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are oxyphenbutazone-specific solicitations. The code shows minimal relevant recent activity, and the three opportunities on record appear to be tagged to this code as a classification mismatch rather than reflecting genuine demand for oxyphenbutazone itself.

The issuing bodies include Seminole County, Florida (an IFB for naloxone and drug deactivation systems with a due date of July 26, 2023), the Texas Health and Human Services Commission (an RFI for direct-to-manufacturer prescription capabilities posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026). Geographic activity spans Florida, Texas, and Minnesota, with cooperative purchasing mechanisms extending to Oregon and other participating jurisdictions. The naloxone solicitation is operational and recurring (quarterly deliveries, two-year term with one-year renewal option), while the Texas HHS RFI is exploratory market research preceding formal procurement, and the MMCAP RFP is a competitive multi-award vehicle. No firm evidence supports sustained procurement demand under this specific code; business development teams evaluating this code should verify current market classification and confirm whether oxyphenbutazone itself is a state or local procurement priority before committing pursuit resources.